CLINICAL TRIALS PROFILE FOR GUSELKUMAB
✉ Email this page to a colleague
All Clinical Trials for guselkumab
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01866007 ↗ | A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants | Completed | Janssen Research & Development, LLC | Phase 1 | 2013-05-09 | The purpose of this study is to evaluate the pharmacokinetic (what the body does to the medication) comparability of guselkumab in lyophilized and liquid formulations. Also to evaluate pharmacokinetic comparability of liquid formulation of guselkumab when delivered as prefilled syringe with UltraSafe Passive Delivery System [PFS-U] or with a prefilled syringe facilitated injection device [PFS FID]) following a single subcutaneous (SC) administration of 100 mg guselkumab in healthy participants. |
NCT02155192 ↗ | An Exploratory Genetic Study in Participants With Psoriasis | Completed | Janssen Research & Development, LLC | 2014-03-01 | The purpose of this study is to evaluate the association between genetic factors and response to treatment (guselkumab, ustekinumab, adalimumab, or etanercept) and psoriasis (scaly skin rash). | |
NCT02203032 ↗ | A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab | Completed | Janssen Research & Development, LLC | Phase 3 | 2014-10-07 | The purpose of this study is to evaluate the efficacy and safety of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash) who had inadequate response to ustekinumab. |
NCT02207231 ↗ | A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis | Completed | Janssen Research & Development, LLC | Phase 3 | 2014-11-26 | The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis. |
NCT02207244 ↗ | A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment | Completed | Janssen Research & Development, LLC | Phase 3 | 2014-11-03 | The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash). |
NCT02319759 ↗ | Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA) | Completed | Janssen Research & Development, LLC | Phase 2 | 2015-03-27 | The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in participants with Active Psoriatic Arthritis (PsA). |
NCT02325219 ↗ | An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis | Completed | Janssen Pharmaceutical K.K. | Phase 3 | 2014-12-19 | The purpose of this study is to demonstrate the superiority of CNTO 1959 (guselkumab) to placebo in the treatment of participants with moderate to severe plaque-type psoriasis (A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for guselkumab
Condition Name
Clinical Trial Locations for guselkumab
Trials by Country
Clinical Trial Progress for guselkumab
Clinical Trial Phase
Clinical Trial Sponsors for guselkumab
Sponsor Name